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The etiology of calcific aortic stenosis (AS) is multifactorial,
involving genetic and environmental factors, including con-
genital valve abnormalities and cardiovascular risk factors
such as smoking, hypercholesterolemia, hypertriglyceride-
mia, diabetes mellitus, and chronic kidney disease (1). Not
ong ago, the cause of aortic valve calcification was thought
o be a “senile” and passive process of natural aging. With
he discovery of bone-related proteins in calcified cardiac
alves along with inflammatory cells, the pathological pro-
ess of cardiac valve calcification was evidently more com-
licated and resembled atherosclerosis (2). Lamellar bone
roduced by endochondral calcification was documented in
3% of surgically excised aortic valves and clearly showed
hat an active process of tissue metamorphosis was present
n a subset of patients with end-stage aortic valve disease (3).
one formation appeared only in valves that also had
ineralized with hydroxyapatite crystal, so-called dystro-
hic calcification. So, how do osteoblasts and osteoclasts
rrive in calcified aortic valves? Are they derived from cells
ndogenous to the valve or do they migrate in from
irculating osteoprogenitor cells, or perhaps both?
See page 1945
A series of investigative findings now indicate that circulat-
ing osteogenic precursor (COP) cells participate in heterotopic
ossification after hip arthroplasty, in a genetic syndrome of
extraskeletal bone formation (fibrodysplasia ossificans progres-
siva [FOP]), and in end-stage aortic valvular disease, as well as
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contents of this paper to disclose.in animal models of ectopic bone formation (4). Suda et al. (5)
identified COP cells as a bone marrow–derived type I colla-
gen osteocalcin (OCN) CD45 subpopulation of mono-
uclear adherent cells that are present in early (pre-osseous)
esions in patients with FOP that can nucleate heterotopic
ssification in a murine in vivo implantation model. Blood
amples from patients with FOP and active inflammatory
xacerbations that led to heterotopic ossification contain sig-
ificantly higher numbers of clonally derived COP cell colonies
han from those of patients with stable disease or unaffected
ndividuals. The possibility that circulating, hematopoietically
erived cells with osteogenic potential can seed inflammatory
ites prompted the histological analysis of aortic valves removed
rom patients with end-stage aortic valve disease.
Egan et al. (6) showed that CD45 OCN COP cells
represent up to 1.1% of mononuclear cells and that COP cells
contribute to early valve heterotopic ossification lesions. Of
note, COP cells were negligible in regions of unaffected valve
leaflets (no heterotopic ossification) from the same individuals.
Although it is widely held that cells with an osteoblast-like
phenotype are present in calcified aortic valves and that they
can differentiate into bone-forming cells, the study by Egan et
al. was the first to provide evidence that osteogenic progenitor
cells may home to sites of vascular injury and inflammation,
and once resident, contribute to heterotopic ossification.
In this issue of the Journal, Gössl et al. (7) report the role of
circulating endothelial progenitor cells (EPCs) with osteoblas-
tic phenotype (EPC-OCN) and osteogenic potential in hu-
man aortic valve calcification. The surface markers of the
EPC-OCN population included CD34, KDR, and CD133,
in addition to the bone protein OCN. Circulating EPC-OCN
cells were studied in healthy controls and patients with varying
degrees of aortic valve calcification. Patients with both severe
AS and severe coronary artery disease (CAD) had significantly
reduced numbers of circulating EPCs (CD34/KDR/
OCN-) compared with controls, but a high percentage of these
circulating EPCs were osteoblastic (EPC-OCN). Patients
with only mild to moderate AS and normal coronary arteries
had an EPC/EPC-OCN profile similar to that of patients
with both severe AS and severe CAD. In contrast, patients
with severe AS and normal coronaries showed normal EPC
and high EPC-OCN numbers with a high percentage of EPC
costaining for OCN. The authors hypothesized that patients
with severe AS but normal coronary arteries may represent a
subgroup of patients whose bone marrow is capable of a surge
of EPC release in response to injury, leading to a more
favorable EPC/EPC-OCN profile. One wonders if this pro-
cess may involve an endothelial to mesenchymal transition, as
noted for other forms of heterotopic ossification (8). Of note,
he authors do not rule out the possibility that resident
ndothelial cells or pre-endothelial cells might contribute to
he ossification process. In contrast, patients with both severe
S and severe CAD may not be capable of such a surge, and
hus show progression of calcific atherosclerosis in multiple
ascular territories due to an unfavorable imbalance between
1955JACC Vol. 60, No. 19, 2012 Mohler et al.
November 6, 2012:1954–5 Aortic Valve Calcificationinjury and repair (i.e., low EPC numbers with a high percent-
age of osteoblastic phenotype).
In summary, our current knowledge of calcific AS is
rapidly evolving. Results of several recent investigations
suggest that circulating hematopoietically derived cells with
osteogenic potential are involved in the process of AS. It
should not be forgotten that AS also is an inflammatory
process and that progression of valve stenosis is likely
directly related to pathological inflammation (9,10). Addi-
tional research is needed to determine the pathological
mechanism(s) by which COP cells result in ossification. If
COP cells are found predicative of aortic valve calcification
and/or ossification, then an in vitro diagnostic test may
make its way into the clinic. The scientific field of cytomics,
the study of circulating cells, is yielding new insights into
mechanisms of disease, including calcific AS.
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